Protein biomarker discovery and validation: the long and uncertain path to clinical utility

By N. Rifai, Michael A. Gillette, Steven A. Carr. Nature Biotechnology, 2006

1,820 citations recorded by the source corpus.

Subfields: Molecular Biology, Spectroscopy

View Paper: https://www.semanticscholar.org/paper/85dc41bcc85925e00a2e0ab3feef79853431dc45

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

In Spectroscopy

Citations in the corpus

Quantitative, Multiplexed Assays for Low Abundance Proteins in Plasma by Targeted Mass Spectrometry and Stable Isotope Dilution*S (2007, background): “De novo proteomics discovery experiments often result in tens to hundreds of candidate biomarkers that must be subsequently verified in plasma (3).”
Statistical strategies for avoiding false discoveries in metabolomics and related experiments (2007, background): “Several years on, ''there are no clear success stories in which discovery proteomics has led to a deployed protein biomarker'' (Rifai et al., 2006).”
Revisiting biomarker discovery by plasma proteomics (2017, background): “Instead, a stepwise or “triangular” strategy for biomarker discovery has been advocated, with several phases in which the number of individuals increases from a few to many, whereas the number of proteins decreases from hundreds or thousands to just a few (Rifai et al, 2006; Fig 3A).”
PaxDb, a Database of Protein Abundance Averages Across All Three Domains of Life (2012, background): “…such measurements are arguably among the most biologically meaningful functional genomics data sets; they support multiple application scenarios, including genome annotation (5, 6), biomarker discovery (7, 8), posttranslational modification detection (9), and even environmental studies (10, 11).”
Circulating microRNAs as stable blood-based markers for cancer detection (2008, methodology): “, qRT-PCR) suggests that the discovery–validation pipeline for miRNA biomarkers will be more efficient than traditional proteomic biomarker discovery–validation pipelines, which typically encounter bottlenecks at the point of antibody generation and quantitative assay development for validation of b”
Multi-site assessment of the precision and reproducibility of multiple reaction monitoring–based measurements of proteins in plasma (2009, background): “In this context, it is highly desirable to verify, by more targeted quantitative methods, the levels of candidate biomarkers in body fluids, cells, tissues or organs from healthy individuals and affected patients in large enough sample numbers to confirm statistically relevant difference”
Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury (2013, background): “However, AKI is also challenging because traditional methods of biomarker discovery often rely on model systems where pathogenesis is well understood or on tissues taken from patients with disease [18] and, since biopsies are rarely obtained from [TIMP-2]•[IGFBP7]”